Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Buloxibutid · 1 trial · 1 indication
• Absolute change from baseline in FVC (mL) at week 52
| Arm | Type | Description |
|---|---|---|
| Buloxibutid 100 mg BID | EXPERIMENTAL | For 52 weeks. |
| Buloxibutid 50 mg BID | EXPERIMENTAL | For 52 weeks. |
| Placebo BID | PLACEBO_COMPARATOR | For 52 weeks. |
| Name | Type | Description |
|---|---|---|
| Buloxibutid | DRUG | Buloxibutid |
| Placebo | DRUG | Placebo |
Inclusion Criteria 1. Age ≥ 40 years at the time of signing the informed consent. 2. Diagnosed with IPF within 7 years prior to visit 1, as per applicable ATS/ERS/JRS/ALAT guidelines at the time of diagnosis. 3. HRCT scan within 36 months prior to visit 1 with central reading confirming either a or...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
Buloxibutid is an investigational small molecule being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Buloxibutid is being developed by Vicore Pharma Holding AB, a biopharmaceutical company listed on the stock exchange under the ticker VCRE. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with Idiopathic Pulmonary Fibrosis.
Buloxibutid is in Phase 2 clinical development. It is currently being evaluated in an active, not recruiting clinical trial (NCT06588686) that is randomized, double-blind, and placebo-controlled, with an enrollment of 378 participants.
Buloxibutid is being studied in a Phase 2 clinical trial with the identifier NCT06588686. This trial is evaluating the efficacy and safety of Buloxibutid in people with Idiopathic Pulmonary Fibrosis. The study is active but not recruiting participants and includes 378 patients across multiple countries.
Buloxibutid is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for Idiopathic Pulmonary Fibrosis. The drug has not yet completed the clinical development process required for regulatory approval.